Abstract
CAPRI is a randomised phase III trial comparing digital and NNs intervention versus usual care in patients (pt) treated with oral anticancer agents (OAA) at Gustave Roussy cancer Center. Results showed that CAPRI intervention improved Relative Dose Intensity, patient experience, grade 3 toxicities and optimised hospitalisation . The aim of this longitudinal analysis is to describe NNs activity data in order to understand how NNs monitoring could be optimised for implementation and sustainability.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
